Ligand validation:2OIQ

STI: 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE

STI is a Ligand Of Interest in 2OIQ designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2OIQ_STI_A_1001	74%	10%	0.121	0.952	2.44	1.94	20	9	0	0	100%	1
3OEZ_STI_A_601	77%	11%	0.119	0.96	2.37	1.87	19	9	2	0	100%	1
3PYY_STI_A_3	95%	47%	0.061	0.963	0.95	1.1	2	3	2	0	100%	1
3K5V_STI_A_2	89%	24%	0.092	0.971	1.1	1.97	2	6	2	0	100%	1
6HD4_STI_A_604	88%	24%	0.096	0.971	1.16	1.96	3	9	0	0	100%	1
3MSS_STI_D_1	87%	19%	0.09	0.961	1.23	2.21	3	18	2	0	100%	1
3GVU_STI_A_1001	85%	20%	0.104	0.968	1.17	2.16	3	10	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.